PHASE I STUDY OF INTRAPERITONEAL RADIOIMMUNOTHERAPY WITH 131I-8H9 FOR PATIENTS WITH DESMOPLASTIC SMALL ROUND CELL TUMORS AND OTHER SOLID TUMORS INVOLVING THE PERITONEUM.

Trial Profile

PHASE I STUDY OF INTRAPERITONEAL RADIOIMMUNOTHERAPY WITH 131I-8H9 FOR PATIENTS WITH DESMOPLASTIC SMALL ROUND CELL TUMORS AND OTHER SOLID TUMORS INVOLVING THE PERITONEUM.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 May 2017

At a glance

  • Drugs Burtomab I 131 (Primary)
  • Indications Peritoneal cancer; Soft tissue sarcoma
  • Focus Adverse reactions
  • Most Recent Events

    • 02 May 2017 Planned End Date changed from 1 Apr 2017 to 1 Apr 2018.
    • 02 May 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2018.
    • 26 Jan 2016 Planned End Date changed from 1 Apr 2016 to 1 Apr 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top